Stock Events

Stock Events

Ocugen 

$1.79
768
-$0.03-1.65% Thursday 03:03

Statistics

Day High
1.83
Day Low
1.79
52W High
-
52W Low
-
Volume
39,762
Avg. Volume
-
Mkt Cap
559.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1MayExpected
Q3 2025
Q4 2025
Next
-0.07
-0.06
-0.06
-0.05
Expected EPS
-0.051429
Actual EPS
N/A

Financials

-1,333.02%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
8.11MRevenue
-108.11MNet Income

Analyst Ratings

$9.00Average Price Target
The highest estimate is 10.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCGN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a competitor because it focuses on mRNA technology for vaccines, including COVID-19, similar to Ocugen's focus on developing a COVID-19 vaccine.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes directly with Ocugen in the COVID-19 vaccine space, having developed one of the first mRNA vaccines for the virus.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor due to its work on developing protein-based vaccines for COVID-19, offering an alternative to Ocugen's vaccine approach.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a major player in the COVID-19 vaccine market, competing with Ocugen through its collaboration with BioNTech to develop an mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson competes with Ocugen by offering a viral vector COVID-19 vaccine, providing a different technology approach in the same market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is in competition with Ocugen due to its viral vector vaccine for COVID-19, which is a direct alternative to Ocugen's vaccine development efforts.
Inovio Pharmaceuticals
INO
Mkt Cap124.89M
Inovio Pharmaceuticals is a competitor because it is developing DNA-based vaccines for COVID-19, positioning it as an alternative to Ocugen's vaccine technology.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma competes with Ocugen in the broader field of biopharmaceuticals, focusing on viral diseases and vaccine technologies.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline is a competitor because it is involved in the development and distribution of vaccines, including efforts towards COVID-19, competing in the same market as Ocugen.

About

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Show more...
CEO
ISIN
US67577C1053

Listings

F
DE
2H51.F
MX
MX
OCGN.MX
XNAS
US
OCGN
BOATS
BOATS
OCGN.BOATS

0 Comments

Share your thoughts

FAQ

What is Ocugen stock price today?▼
The current price of OCGN.BOATS is $1.79 USD — it has decreased by -1.65% in the past 24 hours. Watch Ocugen stock price performance more closely on the chart.
What is Ocugen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ocugen stocks are traded under the ticker OCGN.BOATS.
What is Ocugen market cap?▼
Today Ocugen has the market capitalization of 559.05M
When is the next Ocugen earnings date?▼
Ocugen is going to release the next earnings report on May 01, 2026.
What were Ocugen earnings last quarter?▼
OCGN.BOATS earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.06 USD resulting in a -2.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ocugen revenue for the last year?▼
Ocugen revenue for the last year amounts to 8.11M USD.
What is Ocugen net income for the last year?▼
OCGN.BOATS net income for the last year is -108.11M USD.
When did Ocugen complete a stock split?▼
Ocugen has not had any recent stock splits.